首页> 中文期刊> 《中华医学杂志(英文版)》 >Curcumin Inhibits Lipopolysaccharide-Induced Mucin 5AC Hypersecretion and Airway Inflammation via Nuclear Factor Erythroid 2-Related Factor 2

Curcumin Inhibits Lipopolysaccharide-Induced Mucin 5AC Hypersecretion and Airway Inflammation via Nuclear Factor Erythroid 2-Related Factor 2

         

摘要

Background:Excess mucus production is an important pathophysiological feature of chronic inflammatory airway diseases.Effective therapies are currently lacking.The aim of the study was to evaluate the effects of curcumin (CUR) on lipopolysaccharide (LPS)-induced mucus secretion and inflammation,and explored the underlying mechanism in vivo and in vitro.Methods:For the in vitro study,human bronchial epithelial (NCI-H292) cells were pretreated with CUR or vehicle for 30 min,and then exposed to LPS for 24 h.Next,nuclear factor erythroid 2-related factor 2 (Nrf2) was knocked down with Nrf2 small interfering RNA (siRNA) to confirm the specific role of Nrf2 in mucin regulation of CUR in NCI-H292 cells.In vivo,C57BL/6 mice were randomly assigned to three groups (n =7 for each group):control group,LPS group,and LPS + CUR group.Mice in LPS and LPS + CUR group were injected with saline or CUR (50 mg/kg) intraperitoneally 2 h before intratracheal instillation with LPS (100 μg/ml) for 7 days.Cell lysate and lung tissue were obtained to measured Mucin 5AC (MUC5AC) and Nrf2 mRNA and protein expression by a real-time polymerase chain reaction and Western blotting.Bronchoalveolar lavage fluid (BALF) was collected to enumerate total cells and neutrophils.Histopathological changes of the lung were observed.Data were analyzed by one-way analysis of variance.Student's t-test was used when two groups were compared.Results:CUR significantly decreased the expression ofMUC5AC mRNA and protein in NCI-H292 cells exposed to LPS.This effect was dose dependent (2.424 ± 0.318 vs.7.169 ± 1.785,t =4.534,and 1.060 ± 0.197 vs.2.340 ± 0.209,t =7.716;both P < 0.05,respectively) and accompanied by increased mRNA and protein expression of Nrf2 (1.952 ± 0.340 vs.1.142 ± 0.176,t =-3.661,and 2.010 ± 0.209 vs.1.089 ± 0.132,t =-6.453;both P< 0.05,respectively).Furthermore,knockdown o f Nrf2 with siRNA increased MUC5ACmRNA expression by 47.7%,compared with levels observed in the siRNA-negative group (6.845 ± 1.478 vs.3.391 ± 0.517,t =-3.821,P < 0.05).Knockdown of Nrf2 with siRNA also markedly increased MUC5A C protein expression in NCI-H292 cells.CUR also significantly decreased LPS-induced mRNA and protein expression of MUC5A C in mouse lung (1.672 ± 0.721 vs.5.961 ± 2.452,t =2.906,and 0.480 ± 0.191 vs.2.290 ± 0.834,t =3.665,respectively;both P < 0.05).Alcian blue/periodic acid-Schiff staining also showed that CUR suppressed mucin production.Compared with the LPS group,the numbers of inflammatory cells (247 ± 30 vs.334 ± 24,t =3.901,P < 0.05) and neutrophils (185 ± 22 vs.246 ± 20,t =3.566,P < 0.05) in BALF decreased in the LPS + CUR group,as well as reduced inflammatory cell infiltration in lung tissue.Conclusion:CUR inhibits LPS-induced airway mucus hypersecretion and inflammation through activation of Nrf2 possibly.

著录项

  • 来源
    《中华医学杂志(英文版)》 |2018年第14期|1686-1693|共8页
  • 作者单位

    Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China;

    Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, China;

    Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China;

    Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, China;

    Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China;

    Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, China;

    Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China;

    Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, China;

    Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China;

    Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, China;

    Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China;

    Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号